Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 28;16(1):104.
doi: 10.1007/s11657-021-00964-z.

Zoledronate-induced acute anterior uveitis: a three-case report and brief review of literature

Affiliations
Review

Zoledronate-induced acute anterior uveitis: a three-case report and brief review of literature

Xue Jin et al. Arch Osteoporos. .

Abstract

Purpose: This three-case report aims to highlight the ocular adverse effects induced by bisphosphonate therapy and to call clinicians' attention.

Methods: Three cases of acute anterior uveitis secondary to the initial dose of zoledronate infusion were reported with focus on their symptoms, treatment regimens, and outcomes. A review of published reports provided a basis for discussion.

Results: Three cases of acute anterior uveitis were either bilateral or unilateral. They demonstrated typical manifestations of bisphosphonate-induced acute anterior uveitis such as eye pain, blurred vision, conjunctival and ciliary hyperemia, keratic precipitates, and flare in the anterior chamber. After topical corticosteroid-containing comprehensive treatments, these symptoms resolved completely without any vision loss and long-term sequelae.

Conclusions: Acute anterior uveitis may be part of the acute phase reaction induced by zoledronate. Patients should be informed of its symptoms in advance and be monitored closely during and after administration. Clinicians should have a good awareness of the zoledronate-associated acute anterior uveitis and to treat it in a prompt and appropriate manner.

Keywords: Adverse drug reactions; Bisphosphonate; Uveitis; Zoledronate; Zoledronic acid.

PubMed Disclaimer

Conflict of interest statement

None.

Comment in

References

    1. Belliveau MJ, Almeida DR, Urton TE. Acute anterior uveitis following zoledronic acid infusion for osteoporosis. Can J Ophthalmol. 2012;47(5):e22–23. doi: 10.1016/j.jcjo.2012.03.020. - DOI - PubMed
    1. Rathnam KK, Sagar TG, Cyriac S. Acute uveitis following zoledronic acid infusion. Oman J Ophthalmol. 2009;2(2):102–103. doi: 10.4103/0974-620X.53046. - DOI - PMC - PubMed
    1. Kilickap S, Ozdamar Y, Altundag MK, Dizdar O. A case report: zoledronic acid-induced anterior uveitis. Med Oncol. 2008;25(2):238–240. doi: 10.1007/s12032-007-9006-2. - DOI - PubMed
    1. Umunakwe OC, Herren D, Kim SJ, Kohanim S. Diffuse ocular and orbital inflammation after zoledronate infusion-case report and review of the literature. Digit J Ophthalmol. 2017;23(4):18–21. doi: 10.5693/djo.02.2017.08.002. - DOI - PMC - PubMed
    1. Keren S, Leibovitch I, Ben Cnaan R, Neudorfer M, Fogel O, Greenman Y, Shulman S, Zur D, Habot-Wilner Z. Aminobisphosphonate-associated orbital and ocular inflammatory disease. Acta Ophthalmol. 2019;97(5):e792–799. doi: 10.1111/aos.14063. - DOI - PubMed

MeSH terms

LinkOut - more resources